Overview

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.

Phase:

PHASE2

Details

Lead Sponsor:

University of Arkansas

Treatments:

Naltrexone